Table 2.
Demographic and clinical information.
| ADNI |
1Florida ADRC |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CN | EMCI | LMCI | AD | Statistics | CN | EMCI | LMCI | AD | Statistics | |
| N | 26 | 45 | 26 | 29 | – | 29 | 29 | 25 | 29 | – |
| Age | 72.8 (6.6) | 72.7 (8.0) | 73.2 (6.0) | 73.9 (8.5) | F = 0.17, p = .92 | 67.9 (10.0) | 72.8 (7.2) | 73.6 (7.4) | 72.2 (9.6) | F = 2.4, p = .07 |
| Sex (M/F) | 12/14 | 30/15 | 17/9 | 16/13 | χ2 = 3.5, p = .32 | 10/19 | 10/19 | 14/11 | 16/13 | χ2 = 4.7, p = .19 |
| Years of Education | 16.5 (2.6) | 16.0 (2.6) | 15.5 (2.8) | 14.7 (2.9) | F = 2.3, p = .08 | 16.2 (3.1) | 15.4 (3.5) | 14.7 (3.3) | 14.0 (4.1) | F = 2.05,p = .11 |
| CDR-SB | 0.02 (0.09) | 1.2 (0.7) | 1.6 (0.9) | 4.7 (1.4) | F = 143.2, p = 8.5E-40 | 0.3 (0.9) | 0.9 (0.4) | 2.9 (0.9) | 6.7 (3.3) | F = 76.3, p = 9.4E-27 |
| MMSE | 28.8 (1.4) | 28.0 (1.6) | 27.4 (2.0) | 23.6 (2.0) | F = 51.3, p = 1.6E-21 | 29.1 (1.0) | 27.7 (2.4) | 25.7 (2.7) | 21.4 (5.9) | F = 1.6, p = 4.2E-12 |
| MoCA | 26.2 (2.4) | 23.6 (2.4) | 21.6 (2.3) | 17.8 (4.7) | F = 37.2, p = 4.0E-17 | 24.9 (2.8) | 23.0 (3.1) | 22.2 (10.1) | 14.2 (6.3) | F = 14.57, p = 7.0E-8 |
| Amyloid Status (−/+) |
24/0 | 23/18 | 6/18 | 4/25 | χ2 = 41.8, p = 4.5E-9 | 25/0 | 16/6 | 13/9 | 7/15 | χ2 = 25.6, p = .0002 |
| ApoE ε4 Carriers (0/1+) | 18/7 | 28/16 | 5/20 | 9/19 | χ2 = 20.7, p = .0001 | 20/6 | 21/8 | 10/13 | 19/7 | χ2 = 7.8, p = .05 |
| Intercranial Volume (L) |
1.41 (0.14) | 1.49 (0.14) | 1.48 (0.12) | 1.42 (0.16) | F = 2.0, p = .116 | 1.34 (0.13) | 1.36 (0.17) | 1.40 (0.18) | 1.42 (0.21) | F = 1.36, p = .26 |
Data are either count or mean (±SD). Abbreviations: AD = Alzheimer's disease, ApoE = apolipoprotein, CDR-SB = clinical dementia rating- sum of boxes, CN = Cognitively Normal, EMCI = Early Mild Cognitive Impairment, F = female, ICV = Intracranial Volume, L = Liters, LMCI = Late Mild Cognitive Impairment, M = male, MMSE = Mini-Mental State Examination, MoCA = Montreal Cognitive Assessment.